obecabtagene autoleucel
obecabtagene autoleucel: 5 clinical trials tracked.
obecabtagene autoleucel evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about obecabtagene autoleucel, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (5)
A Phase II Trial of Obecabtagene Autoleucel Consolidation in Adult Patients With Acute Lymphoblastic Leukemia in First Complete Remission Without Measurable Residual Disease
Primary endpoint: relapse free survival (RFS) (Cohort A)
A Single-Arm, Open-Label, Phase II Study to Determine the Safety and Efficacy of Obecabtagene Autoleucel (Obe-cel) in Participants With Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
Primary endpoint: Proportion of participants who achieve complete renal response (CRR)
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
Primary endpoint: Safety and Adverse Events (AEs)
A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis
Primary endpoint: Percentage of participants receiving obe-cel who experience dose-limiting toxicities (DLTs))
A Single-Arm, Open-Label, Phase I Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients With Severe, Refractory Systemic Lupus Erythematosus
Primary endpoint: Dose-limiting toxicities